65,437 trials
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (Site Read, Investigator Assessment) — 98; 107 Patients with a progression event — p=0.273
Healthy
Primary: Number of Subjects With Drug Related Adverse Events (AE) — 2; 0; 0; 0 participants
End Stage Renal Disease
Primary: Maximum Plasma Concentration (Cmax) of Oseltamivir in HD Participants During Days 1 to 5 — 20.2 ng/mL
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase I — 0; 0; 0; 0 participants
Neoplasms
Primary: MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib). — NA; 40 mg
Cancer · Leukemia · Myelodysplastic Syndrome
Primary: Overall Response — 24; 3 participants
Meniere's Disease
Primary: Vestibular "Endolymphatic Hydrops (EH)" — 0; 4; 2 participants
Acute Coronary Syndrome
Primary: The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding — 5.1; 8.5 percentage of participants — p=0.0014
Acute Myocardial Infarction
Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L
Hepatitis C, Chronic
Primary: SVR12 Rates With Historical Control — 79.95; 76.68; 88.28; 70.78 percentage of participants — p=<0.0001
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Intraocular Melanoma
Primary: Overall Response Rate — 0 patients
Gout
Primary: Number of Subjects With an sUA Level That is < 6.0 mg/dL — 32; 2 Number of Subjects — p=<0.0001
Recurrent Breast Carcinoma · Stage IIIB Breast Cancer · Stage IIIC Breast Cancer
Primary: Number of Participants With Response Defined Using Response Evaluation Criteria In Solid Tumors (RECIST) — 0; 1; 20; 0 participants
Prostate Cancer
Primary: Response Rate — 9.3 percentage of participants